NetScientific (NSCI), an international life sciences and sustainability technology investment and commercialisation Group, reported on 14 November (yesterday at 14:50) that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB) had provided financial results for Q3 2022 (to 30 September) together with a business update. PDSB achieved a number of milestones in the year to date in connection with four ongoing Phase II clinical trials for its lead candidate, PDS0101 as well as announci ....
15 Nov 2022
WH Ireland: NetScientific (NSCI) - PDS Biotech Q3 results – Positive clinical data announced at SITC 2022
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
WH Ireland: NetScientific (NSCI) - PDS Biotech Q3 results – Positive clinical data announced at SITC 2022
NetScientific plc (NSCI:LON) | 63.0 0 0.0% | Mkt Cap: 15.1m
- Published:
15 Nov 2022 -
Author:
Matthew Davis | Emma Ulker -
Pages:
5
NetScientific (NSCI), an international life sciences and sustainability technology investment and commercialisation Group, reported on 14 November (yesterday at 14:50) that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB) had provided financial results for Q3 2022 (to 30 September) together with a business update. PDSB achieved a number of milestones in the year to date in connection with four ongoing Phase II clinical trials for its lead candidate, PDS0101 as well as announci ....